[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.16\u2033 kilitli=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.16\u2033 arka plan_size=\u201dinitial\u201d arka plan_position=\u201dtop_left\u201d arka plan_repeat=\u201dtekrar\u201d global_colors_info=\u201d{ }\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201dcustom_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.23.1\u2033header_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat=\u201drepeat\u201dcustom_padding =\u201d25px||||false|false\u201d global_colors_info=\u201d{}\u201d]<\/p>\n
Ya\u015fam tarz\u0131 fakt\u00f6rleri a\u011f\u0131z kanserinin geli\u015fiminde \u00f6nemli bir rol oynamaktad\u0131r. Bir\u00e7ok klinik risk fakt\u00f6r\u00fc aras\u0131nda sigara ve alkol, hastan\u0131n a\u011f\u0131z kanseri riskini do\u011frudan art\u0131ran davran\u0131\u015flar\u0131n ba\u015f\u0131nda gelir. Sigara i\u00e7mek tek ba\u015f\u0131na a\u011f\u0131z kanseri riskini 10 kat art\u0131r\u0131yor.1<\/sup> ve a\u015f\u0131r\u0131 alkol t\u00fcketimi riski be\u015f kat art\u0131r\u0131r.2<\/sup><\/p>\n Ancak bu ya\u015fam tarz\u0131 fakt\u00f6rleri birbirini d\u0131\u015flayan de\u011fildir. Alkol ba\u011f\u0131ml\u0131l\u0131\u011f\u0131 olan hastalar\u0131n sigara i\u00e7me olas\u0131l\u0131\u011f\u0131 \u00fc\u00e7 kat daha fazla, t\u00fct\u00fcn ba\u011f\u0131ml\u0131s\u0131 hastalar\u0131n ise alkol ba\u011f\u0131ml\u0131s\u0131 olma olas\u0131l\u0131\u011f\u0131 d\u00f6rt kat daha fazlad\u0131r.3<\/sup> \u00dcstelik alkol t\u00fcketimi, sigara i\u00e7me s\u0131kl\u0131\u011f\u0131yla do\u011frudan ili\u015fkilidir ve her iki maddenin de y\u00fcksek oranda kullan\u0131lmas\u0131, a\u011f\u0131z kanseri gibi olumsuz sa\u011fl\u0131k etkilerinin ortaya \u00e7\u0131kma riskini katlanarak art\u0131r\u0131r.<\/p>\n Sigara ve alkol tek ba\u015f\u0131na a\u011f\u0131z kanserine yakalanma olas\u0131l\u0131\u011f\u0131n\u0131 art\u0131r\u0131rken, birlikte hastan\u0131n riskini 30 kata kadar art\u0131r\u0131r.4<\/sup> Bu rakam, \u00f6zellikle ya\u015f (vakalar\u0131n 80%'si 55 ya\u015f\u0131n \u00fczerindeki hastalarda g\u00f6r\u00fcl\u00fcr) ve cinsiyet (erkeklerde a\u011f\u0131z kanserine yakalanma olas\u0131l\u0131\u011f\u0131 iki kat daha fazlad\u0131r) gibi ek klinik risk fakt\u00f6rleriyle daha da artmaktad\u0131r.5<\/sup><\/p>\n Bu sinerjistik etkinin kesin nedeni bilinmemektedir, ancak baz\u0131 mekanizmalar ara\u015ft\u0131r\u0131lm\u0131\u015f ve \u00f6nerilmi\u015ftir. T\u00fct\u00fcn\u00fcn, h\u00fccresel mekanizmalar\u0131 de\u011fi\u015ftiren ve DNA yap\u0131s\u0131na zarar veren kanserojenleri a\u011f\u0131z bo\u015flu\u011funa soktu\u011fu iyi bilinmektedir. Alkol, t\u00fct\u00fcn katran\u0131n\u0131n kanserojenlere d\u00f6n\u00fc\u015fmesini h\u0131zland\u0131rmas\u0131n\u0131n yan\u0131 s\u0131ra, mukozay\u0131 kaplayan koruyucu dokuyu par\u00e7alayabilir ve bu molek\u00fcllere h\u00fccresel ge\u00e7irgenli\u011fi art\u0131rabilir. Birlikte kullan\u0131ld\u0131\u011f\u0131nda t\u00fct\u00fcn ve alkol, kansere yol a\u00e7an h\u00fccresel d\u00fczeyde a\u011f\u0131z bo\u015flu\u011fu de\u011fi\u015fiklikleri i\u00e7in uygun ortam\u0131 kolayla\u015ft\u0131r\u0131r.<\/p>\n Erken tarama ve te\u015fhis her a\u011f\u0131z kanseri hastas\u0131 i\u00e7in \u00e7ok \u00f6nemlidir, ancak \u00f6zellikle hem t\u00fct\u00fcn hem de alkol kullanan hastalar i\u00e7in hastal\u0131\u011fa yakalanma olas\u0131l\u0131klar\u0131 \u00e7ok daha y\u00fcksektir. Sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131 erken evre belirti ve semptomlar\u0131n tan\u0131nmas\u0131nda \u00f6nemli bir rol oynamaktad\u0131r ve s\u0131kl\u0131kla sigara ve i\u00e7ki i\u00e7en hastalar\u0131 de\u011ferlendirirken \u00e7ok dikkatli olmal\u0131d\u0131rlar.<\/p>\n A\u011f\u0131z kanseri ne kadar erken tespit edilebilirse, hastan\u0131n tedavisi de o kadar etkili ve daha az invaziv olabilir. D\u00fczenli di\u015f muayeneleri, hastalar\u0131n a\u011f\u0131z mukozas\u0131ndaki anormal de\u011fi\u015fiklikleri de\u011ferlendirmek ve izlemek i\u00e7in ideal bir f\u0131rsat sa\u011flar. Bu, a\u015fa\u011f\u0131dakiler de dahil olmak \u00fczere semptomlar i\u00e7in a\u011f\u0131z, dudak, dil ve \u00e7evresindeki alanlar\u0131n kapsaml\u0131 bir incelemesini i\u00e7erir:<\/p>\n Risk fakt\u00f6rlerini kanser geli\u015fmeden \u00f6nce tart\u0131\u015fmak, yaln\u0131zca acil m\u00fcdahaleyi m\u00fcmk\u00fcn k\u0131lmakla kalmaz, ayn\u0131 zamanda hastalar\u0131n a\u011f\u0131z sa\u011fl\u0131\u011f\u0131n\u0131 geli\u015ftiren davran\u0131\u015f ve ya\u015fam tarz\u0131 de\u011fi\u015fiklikleri uygulamalar\u0131na da yard\u0131mc\u0131 olur ve potansiyel olarak a\u011f\u0131z kanseri te\u015fhisini geciktirir. Hastalarda lezyonlar geli\u015fmeye ba\u015flarsa, sa\u011flay\u0131c\u0131lar\u0131 h\u0131zl\u0131 bir \u015fekilde m\u00fcdahale edebilir ve kapsaml\u0131 cerrahi ve rehabilitasyon gerekmeden \u00f6nce tedaviyi ba\u015flatabilir.<\/p>\n Bir hastan\u0131n risk fakt\u00f6r\u00fc profilini anlamak, daha iyi a\u011f\u0131z kanseri sonu\u00e7lar\u0131 elde etmede temel ilk ad\u0131md\u0131r. Bir sonraki ad\u0131m, lezyonlar b\u00fcy\u00fcmeye ba\u015flad\u0131\u011f\u0131nda do\u011fru taramad\u0131r. Vigilant Biosciences\u00ae'\u0131n BeVigilant\u2122 OraFusion\u2122 Sistemi, klinik risk fakt\u00f6rlerini analiz ederek ve t\u00fck\u00fcr\u00fckte bulunan erken a\u015fama biyobelirte\u00e7leri belirleyerek sa\u011flay\u0131c\u0131lar\u0131n tespitini h\u0131zland\u0131rmas\u0131na yard\u0131mc\u0131 olur. Non-invaziv test, bak\u0131m noktas\u0131nda ger\u00e7ekle\u015ftirilir ve 15 dakika veya daha k\u0131sa s\u00fcrede d\u00fc\u015f\u00fck, orta veya y\u00fcksek risk sonucu sa\u011flar. BeVigilant\u2122 OraFusion\u2122 Sistemi FDA onay\u0131n\u0131 bekliyor ancak halihaz\u0131rda Almanya, \u0130talya ve Birle\u015fik Krall\u0131k'ta sonu\u00e7lar\u0131 d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor ve hayat kurtar\u0131yor.<\/p>\n BeVigilant\u2122 OraFusion\u2122 Sisteminin h\u0131zl\u0131 risk de\u011ferlendirmesi yoluyla a\u011f\u0131z kanseri tespitini nas\u0131l iyile\u015ftirdi\u011fi hakk\u0131nda daha fazla bilgi edinin.<\/a><\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u201d4.23.1\u2033 text_font_size=\u201d14px\u201dheader_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat=\u201drepeat\u201d hover_enabled=\u201d0\u2033 global_colors_info =\u201d{}\u201d sticky_enabled=\u201d0\u2033]<\/p>\n Kaynaklar<\/strong><\/p>\n 1. A\u011f\u0131z Kanseri ve T\u00fct\u00fcn<\/em>. (nd). Johns Hopkins T\u0131p. 18 Ekim 2023'te \u015fu adresten al\u0131nd\u0131: https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/oral-cancer-and-tobacco<\/a> [\/et_pb_text][et_pb_text devre d\u0131\u015f\u0131_on=\u201don|on|on\u201d _builder_version=\u201d4.23.1\u2033 text_font_size=\u201d14px\u201dheader_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat= \u201dtekrar\u201d devre d\u0131\u015f\u0131=\u201don\u201d global_colors_info=\u201d{}\u201d]<\/p>\n Kaynaklar<\/strong><\/p>\n 1. Daniel, M. ve Rogers, S.N. (2022). A\u011f\u0131z kanseri olan hastalar\u0131n sevkinde mesleki gecikmeler: alt\u0131 vaka \u00f6yk\u00fcs\u00fc. \u0130ngiliz Di\u015f Dergisi 233(12), 1003-1008. [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":" Ya\u015fam tarz\u0131 fakt\u00f6rleri a\u011f\u0131z kanserinin geli\u015fiminde \u00f6nemli bir rol oynamaktad\u0131r. Bir\u00e7ok klinik risk fakt\u00f6r\u00fc aras\u0131nda sigara ve alkol, hastan\u0131n a\u011f\u0131z kanseri riskini do\u011frudan art\u0131ran davran\u0131\u015flar\u0131n ba\u015f\u0131nda gelir. Tek ba\u015f\u0131na sigara i\u00e7mek a\u011f\u0131z kanseri riskini on kat art\u0131r\u0131r1 ve a\u015f\u0131r\u0131 alkol t\u00fcketimi ise riski 1 kat art\u0131r\u0131r.<\/p>","protected":false},"author":3,"featured_media":598,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-592","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\nSigara ve Alkol: Bile\u015fik Bir Risk<\/h2>\n
Proaktif Taraman\u0131n Rol\u00fc<\/h2>\n
\n
A\u011f\u0131z Kanseri Tespitini \u0130yile\u015ftirmede Bir Sonraki Ad\u0131m\u0131 At\u0131n<\/h2>\n
2. Bagnardi, V., Rota, M., Botteri, E., Tramacere, I., Islami, F., Fedirko, V., Scotti, L., Jenab, M., Turati, F., Pasquali, E ., Pelucchi, C., Galeone, C., Bellocco, R., Negri, E., Corrao, G., Boffetta, P., La Vecchia, C. (2015). Alkol t\u00fcketimi ve b\u00f6lgeye \u00f6zg\u00fc kanser riski: kapsaml\u0131 bir doz-yan\u0131t meta-analizi. \u0130ngiliz Kanser Dergisi 112<\/em>(3), 580-593.
3. Greer, JB, Thrower, E. ve Yadav, D. (2015). Sigara ve Pankreatit Aras\u0131ndaki Epidemiyolojik ve Mekanistik \u0130li\u015fkiler. Gastroenterolojide G\u00fcncel Tedavi Se\u00e7enekleri 13<\/em>(3), 332-346.
4. D\u00fcnya Kanser G\u00fcn\u00fc: Ger\u00e7ekleri bilin; t\u00fct\u00fcn ve alkol kansere neden oluyor<\/em>. (2021, 3 \u015eubat). D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc. https:\/\/www.who.int\/europe\/news\/item\/03-02-2021-world-cancer-day-know-the-facts-tobacco-and-alcohol-both-cause-cancer<\/a>
5. A\u011f\u0131z Bo\u015flu\u011fu ve Orofaringeal Kanserlere \u0130li\u015fkin Temel \u0130statistikler<\/em>. (2023, 18 Ocak). Amerikan Kanser Toplulu\u011fu. https:\/\/www.cancer.org\/cancer\/types\/oral-cavity-and-oropharyngeal-cancer\/about\/key-statistics.html<\/a><\/p>\n
2. A\u011f\u0131z ve Orofaringeal Kanser: \u0130statistikler. (Ekim 2022). Kanser.Net. https:\/\/www.cancer.net\/cancer-types\/oral-and-oropharyngeal-cancer\/statistics<\/a>
3. Gonz\u00e1lez-Moles, M.\u00c1., Aguilar-Ruiz, M. ve Ramos-Garc\u00eda, P. (2022). A\u011f\u0131z Kanserinin Erken Tan\u0131s\u0131ndaki Zorluklar, Kan\u0131t Eksiklikleri ve \u0130yile\u015ftirme Stratejileri: Sistematik \u0130ncelemelerin Kapsaml\u0131 Bir \u0130ncelemesi. Kanserler 14(19), 4967.
4. A\u011f\u0131z Bo\u015flu\u011fu ve Orofaringeal Kanser Cerrahisi. (tarih yok). Amerikan Kanser Toplulu\u011fu. 18 May\u0131s 2023'te \u015fu adresten al\u0131nd\u0131: https:\/\/www.cancer.org\/cancer\/types\/oral-cavity-and-oropharyngeal-cancer\/treating\/surgery.html<\/a>
5. Jacobson, J.J., Epstein, J.B., Eichmiller, F.C., Gibson, T.B., Carls, G.S., Vogtmann, E., Wang, S., Murphy, B. (2012). Oral, oral faringeal ve t\u00fck\u00fcr\u00fck bezi kanserlerinin maliyet y\u00fck\u00fc \u00fc\u00e7 gruptad\u0131r: ticari sigorta, Medicare ve Medicaid. Ba\u015f ve Boyun Onkolojisi 4, 15.<\/p>\n